ENTITY

United Therapeutics (UTHR US)

28
Analysis
Health CareUnited States
United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease. The Company's lead products are stable synthetic forms of prostacyclin and are delivered orally or subcutaneously.
more
Refresh
25 Oct 2016 10:24

Recap of Key Events in the U.S. Biotechnology and Pharmaceutical Sector: October 24 (Monday)

Summary: We discuss Atyr Pharma Inc (LIFE US), DBV Technologies SA (DBV FP), Advaxis Inc (ADXS US), Global Blood Therapeutics Inc (GBT US),...

20 Oct 2016 11:25

Recap of Key Events in the U.S. Biotechnology and Pharmaceutical Sector: Mid-Week Update

Galapagos NV (GLPG NA) seems to have got some investor attention after the successful results of Celgene Corp (CELG US) anti-inflammatory product...

19 Oct 2016 11:19

Recap of Key U.S. Biotechnology and Pharmaceutical Sector Events: October 17

Celgene (NASDAQ: CELG) announced successful phase 1b data of its antisense therapy GED-0301 in the treatment of Crohn's disease (48% remission rate...

07 Jul 2016 10:21

No Pain, Potential for Lots of Gain for Pfizer, Lilly, and Regeneron

The history of pain drugs that target nerve growth factor has been a roller-coaster ride for drug developers and investors. In 2010, expectations...

Logo
169 Views
Share
15 Apr 2016 11:33

Healthcare Observer: Orthopedic Innovation Beyond Large Joint Market Fuels Long-Term Growth

Over the next decade, we expect orthopedic innovation in extremities, robotics, and 3-D printing to be key drivers of growth as fee-for-value...

Logo
199 Views
Share
x